RU2003121231A - SILENT ANTI-CD28 ANTIBODIES AND THEIR APPLICATION - Google Patents

SILENT ANTI-CD28 ANTIBODIES AND THEIR APPLICATION Download PDF

Info

Publication number
RU2003121231A
RU2003121231A RU2003121231/15A RU2003121231A RU2003121231A RU 2003121231 A RU2003121231 A RU 2003121231A RU 2003121231/15 A RU2003121231/15 A RU 2003121231/15A RU 2003121231 A RU2003121231 A RU 2003121231A RU 2003121231 A RU2003121231 A RU 2003121231A
Authority
RU
Russia
Prior art keywords
antibody
seq
host cell
polynucleotide
patient
Prior art date
Application number
RU2003121231/15A
Other languages
Russian (ru)
Other versions
RU2261723C2 (en
Inventor
Дз Юн ЦО (US)
Дз Юн ЦО
Пол ХИНТОН (US)
Пол ХИНТОН
Максимиль но ВАСКЕС (US)
Максимильяно Васкес
Коуити ТАМУРА (JP)
Коуити ТАМУРА
Ясуюки ХИГАСИ (JP)
Ясуюки Хигаси
Нобуо СЕКИ (JP)
Нобуо СЕКИ
Хироцугу УЕДА (JP)
Хироцугу УЕДА
Original Assignee
Фудзисава Фармасьютикал Ко.,Лтд. (Jp)
Фудзисава Фармасьютикал Ко.,Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фудзисава Фармасьютикал Ко.,Лтд. (Jp), Фудзисава Фармасьютикал Ко.,Лтд. filed Critical Фудзисава Фармасьютикал Ко.,Лтд. (Jp)
Publication of RU2003121231A publication Critical patent/RU2003121231A/en
Application granted granted Critical
Publication of RU2261723C2 publication Critical patent/RU2261723C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (25)

1. Молчащее анти-CD28-антитело.1. Silent anti-CD28 antibody. 2. Антитело по п.1, которое является химерным антителом.2. The antibody according to claim 1, which is a chimeric antibody. 3. Антитело по п.1, которое является гуманизированным антителом.3. The antibody according to claim 1, which is a humanized antibody. 4. Антитело по п.1, которое содержит вариабельную область, содержащую аминокислотную последовательность SEQ ID NO: 2 или SEQ ID NO: 4.4. The antibody according to claim 1, which contains a variable region containing the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4. 5. Антитело по п.1, которое содержит вариабельную область, содержащую аминокислотные последовательности SEQ ID NO: 2 и SEQ ID NO: 4.5. The antibody according to claim 1, which contains a variable region containing the amino acid sequence of SEQ ID NO: 2 and SEQ ID NO: 4. 6. Антитело по п.1, которое содержит вариабельную область, содержащую аминокислотную последовательность SEQ ID NO: 6 или SEQ ID NO: 8.6. The antibody according to claim 1, which contains a variable region containing the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 8. 7. Антитело по п.1, которое содержит вариабельную область, содержащую аминокислотные последовательности SEQ ID NO: 6 и SEQ ID NO: 8.7. The antibody according to claim 1, which contains a variable region containing the amino acid sequence of SEQ ID NO: 6 and SEQ ID NO: 8. 8. Полинуклеотид, кодирующий антитело по п.1.8. The polynucleotide encoding the antibody according to claim 1. 9. Полинуклеотид по п.8, который включает, по меньшей мере, один полинуклеотид, выбранный из группы, состоящей из SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 и SEQ ID NO: 4.9. The polynucleotide of claim 8, which includes at least one polynucleotide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4. 10. Экспрессирующий вектор, включающий полинуклеотид по п.8.10. An expression vector comprising the polynucleotide of claim 8. 11. Клетка-хозяин, включающая полинуклеотид по п.8.11. A host cell comprising the polynucleotide of claim 8. 12. Клетка-хозяин, включающая экспрессирующий вектор по п.10.12. A host cell comprising the expression vector of claim 10. 13. Способ получения молчащего анти-CD28-антитела, предусматривающий культивирование клетки-хозяина по п.11 в условиях, подходящих для экспрессии антитела, и выделение экспрессированного антитела из указанной культуры.13. A method for producing a silent anti-CD28 antibody, comprising culturing a host cell according to claim 11 under conditions suitable for expression of the antibody, and isolating the expressed antibody from said culture. 14. Способ получения молчащего анти-CD28-антитела, предусматривающий культивирование клетки-хозяина по п.12 в условиях, подходящих для экспрессии антитела, и выделение экспрессированного антитела из указанной культуры.14. A method for producing a silent anti-CD28 antibody, comprising culturing the host cell of claim 12 under conditions suitable for expression of the antibody, and isolating the expressed antibody from said culture. 15. Способ получения молчащего анти-CD28-антитела, предусматривающий введение полинуклеотида по п.8 в клетку-хозяина; культивирование клетки-хозяина в условиях, подходящих для экспрессии антитела, и выделение экспрессированного антитела из указанной культуры.15. A method of obtaining a silent anti-CD28 antibody, comprising administering the polynucleotide of claim 8 into a host cell; culturing the host cell under conditions suitable for expression of the antibody; and isolating the expressed antibody from said culture. 16. Способ по п.15, в котором указанный полинуклеотид включает, по меньшей мере, один полинуклеотид, выбранный из группы, состоящей из SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 и SEQ ID NO: 4.16. The method of claim 15, wherein said polynucleotide comprises at least one polynucleotide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4 . 17. Способ получения молчащего анти-CD28-антитела, предусматривающий введение экспрессирующего вектора по п.10 в клетку-хозяина; культивирование клетки-хозяина в условиях, подходящих для экспрессии антитела, и выделение экспрессированного антитела из указанной культуры.17. A method of obtaining a silent anti-CD28 antibody, comprising introducing an expression vector of claim 10 into a host cell; culturing the host cell under conditions suitable for expression of the antibody; and isolating the expressed antibody from said culture. 18. Фармацевтическая композиция, включающая молчащее анти-CD28-антитело по п.1 и фармацевтически приемлемый ингредиент.18. A pharmaceutical composition comprising the silent anti-CD28 antibody of claim 1 and a pharmaceutically acceptable ingredient. 19. Способ индукции Т-клеточной толерантности у пациента, предусматривающий введение эффективного количества антитела по п.1 для индукции Т-клеточной толерантности у указанного пациента.19. A method for inducing T-cell tolerance in a patient, comprising administering an effective amount of an antibody according to claim 1 for inducing T-cell tolerance in said patient. 20. Способ по п.19, в котором указанное введение дополнительно предусматривает введение другого иммуносупрессора.20. The method of claim 19, wherein said administration further comprises administering another immunosuppressant. 21. Способ проведения иммуносупрессии у пациента, предусматривающий введение эффективного количества антитела по п.1 для проведения иммуносупрессии у указанного пациента.21. A method for conducting immunosuppression in a patient, comprising administering an effective amount of an antibody according to claim 1 for conducting immunosuppression in said patient. 22. Способ по п.21, в котором указанное введение дополнительно предусматривает введение другого иммуносупрессора.22. The method of claim 21, wherein said administration further comprises administering another immunosuppressant. 23. Способ лечения отторжения трансплантанта органа или ткани у пациента, предусматривающий введение эффективного количества антитела для лечения отторжения трансплантанта органа или ткани у указанного пациента.23. A method of treating organ or tissue transplant rejection in a patient, comprising administering an effective amount of an antibody to treat organ or tissue transplant rejection in said patient. 24. Способ по п.23, в котором указанное введение дополнительно предусматривает введение другого иммуносупрессора.24. The method of claim 23, wherein said administration further comprises administering another immunosuppressant. 25. Антитело, выбранное из группы, состоящей из HuTN228 и MuTN228, и их Fab-фрагментов, и их F(ab')2-фрагментов.25. An antibody selected from the group consisting of HuTN228 and MuTN228, and their Fab fragments, and their F (ab ') 2 fragments.
RU2003121231/15A 2000-12-14 2001-12-14 Silent anti-cd28-antibody and their applying RU2261723C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
US60/255,155 2000-12-14

Publications (2)

Publication Number Publication Date
RU2003121231A true RU2003121231A (en) 2005-02-10
RU2261723C2 RU2261723C2 (en) 2005-10-10

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003121231/15A RU2261723C2 (en) 2000-12-14 2001-12-14 Silent anti-cd28-antibody and their applying

Country Status (18)

Country Link
EP (1) EP1341553A4 (en)
JP (1) JP2004515243A (en)
KR (1) KR20040020866A (en)
CN (1) CN1272345C (en)
AR (1) AR031924A1 (en)
AU (2) AU2608602A (en)
BR (1) BR0116686A (en)
CA (1) CA2432736A1 (en)
CZ (1) CZ20031909A3 (en)
HU (1) HUP0400697A3 (en)
IL (1) IL156262A0 (en)
MX (1) MXPA03005327A (en)
NO (1) NO20032542L (en)
NZ (1) NZ526569A (en)
PL (1) PL363239A1 (en)
RU (1) RU2261723C2 (en)
WO (1) WO2002047721A1 (en)
ZA (1) ZA200305384B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc Self-buffering protein formulations
FR2951176A1 (en) * 2009-10-09 2011-04-15 Tcl Pharma MONOVALENT LIGANDS OF THE HUMAN CD28 RECEPTOR
DK2536764T3 (en) * 2010-02-18 2018-09-17 Ose Immunotherapeutics ANTI-CD28 HUMANIZED ANTIBODIES
JP6884858B2 (en) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド Pharmaceutical product and its manufacturing method
AU2019287765A1 (en) 2018-06-15 2021-01-07 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
JP2022525332A (en) * 2019-03-14 2022-05-12 ビオンド バイオロジクス リミテッド Methods of immunosuppression
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
JP2023509359A (en) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Combination anticancer therapy with inducers of iron-dependent cell degradation
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
JP2023538891A (en) 2020-08-19 2023-09-12 ゼンコア インコーポレイテッド Anti-CD28 composition
KR20230165276A (en) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Thanotransmission polypeptides and their use in the treatment of cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024148336A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. T cell costimulatory multimeric binding molecules and uses thereof
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Also Published As

Publication number Publication date
IL156262A0 (en) 2004-01-04
PL363239A1 (en) 2004-11-15
AU2002226086C1 (en) 2006-03-09
EP1341553A1 (en) 2003-09-10
JP2004515243A (en) 2004-05-27
CZ20031909A3 (en) 2003-11-12
WO2002047721A1 (en) 2002-06-20
MXPA03005327A (en) 2004-12-03
CA2432736A1 (en) 2002-06-20
AU2002226086B2 (en) 2005-08-25
NO20032542D0 (en) 2003-06-05
RU2261723C2 (en) 2005-10-10
HUP0400697A3 (en) 2007-05-02
AR031924A1 (en) 2003-10-08
EP1341553A4 (en) 2004-07-28
CN1489473A (en) 2004-04-14
CN1272345C (en) 2006-08-30
ZA200305384B (en) 2004-10-11
HUP0400697A2 (en) 2004-06-28
BR0116686A (en) 2003-12-30
AU2608602A (en) 2002-06-24
NZ526569A (en) 2005-07-29
NO20032542L (en) 2003-08-07
KR20040020866A (en) 2004-03-09

Similar Documents

Publication Publication Date Title
RU2003121231A (en) SILENT ANTI-CD28 ANTIBODIES AND THEIR APPLICATION
Lanar et al. Identification of paramyosin as schistosome antigen recognized by intradermally vaccinated mice
FI91421C (en) A method for producing a monoclonal antibody reactive with human tumor necrosis factor (TNF) and an antibody-producing hybrid cell line
DE69325577T2 (en) MN GENE AND PROTEIN
CA2212150C (en) Monoclonal antibodies for human osteogenic cell surface antigens
DE69026627T2 (en) ANTIBODY ANTAGONISTS AGAINST HUMANES INTERLEUKIN-4
NO319013B1 (en) Vaccine comprising type I surface antigens from Staphylococcus epidermidis, as well as hyperimmune globulins and antibody directed against the type I surface antigen.
UA119226C2 (en) ANTIBODY THAT SPECIFICALLY BECOMES AXL AND ITS APPLICATION AS A PRODUCT FOR ADDRESSED SHIPPING IN CANCER TREATMENT
RU2009103533A (en) METHODS FOR PRODUCING POLYCLONAL ANTIBODIES, ANTI-SERUM CONTAINING POLYCLONAL ANTIBODIES, AND METHODS OF IMMUNIZATION
RU2000109255A (en) "HUMANIZED" ANTIBODIES AGAINST HUMAN GP39, COMPOSITIONS CONTAINING THESE ANTIBODIES AND THEIR THERAPEUTIC USES
JP4796682B2 (en) Human B lymphoblastoma cell lines producing anti-ganglioside antibodies
WO1996024848A9 (en) Monoclonal antibodies for human osteogenic cell surface antigens
RU2317998C2 (en) Human antibody possessing binding activity with mn and neutralization of cellular adhesion
JPH06505965A (en) β-type transforming growth factor
RU2008138541A (en) METHODS OF DESTRUCTION OF CELLS USING ANTI-EPHA4 ANTIBODIES EFFECTIVE FUNCTIONS
US5084391A (en) Monoclonal antibody to the interleukin-2-receptor and its use
CA2597701A1 (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype
CN112472621B (en) Preparation method of stem cell exosome and medicine or cosmetic prepared by stem cell exosome
CN112707959B (en) Polypeptide, preparation method and application
JPS63501769A (en) Monoclonal antibody against human pluripotent granulocyte colony stimulating factor and method using the antibody
CA2525657A1 (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of serotype iats o6 of pseudomonas aeruginosa
EP0492552A1 (en) Anti-IGF-II monoclonal antibody
NZ225167A (en) Immunosuppresive peptides (minimum 9 residues)
US5565338A (en) Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor
CN100441689C (en) EHEC 0157 shiga-like toxin IIA resisting subunit monoclonal antibody 5F3 light and heavy chain variable region gene and its application

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20061215